Pre-trial implementation study for ketamine in sickle cell disease

氯胺酮治疗镰状细胞病的预试验实施研究

• 批准号: 10526631
• 负责人: Francis J. Keefe
• 金额: $ 30.59万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2023-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10526631
• 关键词: Academic Medical Centers; Acute; Adult; Anesthesiology; Anesthetics; Caring; Chronic; Clinical; Clinical Research; Clinical Trials; Collection; Complex; Consolidated Framework for Implementation Research; Cross-Sectional Studies; Emergency Medicine; Enrollment; Health Professional; Healthcare; Helping to End Addiction Long-term; Hematology; Hospitalists; Hospitals; Infusion procedures; Inpatients; Interview; Ketamine; Medicine; Modeling; Outcome; Pain; Pain Research; Pain management; Patients; Perception; Persons; Pharmacology; Proctor framework; Protocols documentation; Resources; Secondary to; Sickle Cell; Sickle Cell Anemia; Site; Structure; System; United States National Institutes of Health; biomarker validation; chronic pain; clinical biomarkers; clinical pain; community engagement; design; experience; flexibility; healing; implementation outcomes; implementation study; improved; insight; medical specialties; non-opioid analgesic; novel; opioid use

Specific Aim 1: Assess healthcare stakeholders' perceptions of barriers to and facilitators for a RCT of early administration of sub-anesthetic ketamine infusion as a pain adjunct for VOEs using the Consolidated Framework for Implementation Research (CFRIR) and Proctor's taxonomy for implementation outcomes. To achieve this, we will: 1A: Conduct a cross-sectional survey study of healthcare professionals within EPPIC-Net who provide care for people with SCD and/or provide guidance for administration of ketamine within their hospital system (i.e., specialties including hematology, emergency medicine, anesthesiology, and hospitalist medicine) to assess barriers to and facilitators for the proposed RCT 1B: Conduct semi-structured interviews of 15-20 healthcare professionals to assess barriers to and facilitators for the proposed RCT.

具体目标 1：评估医疗保健利益相关者对阻碍和促进医疗保健的看法 亚麻醉氯胺酮输注早期给药作为 VOE 疼痛辅助剂的随机对照试验 使用实施研究综合框架 (CFRIR) 和 Proctor’s 实施结果的分类。为了实现这一目标，我们将： 1A：进行横断面调查 对 EPPIC-Net 内为患有以下疾病的人提供护理的医疗保健专业人员进行的调查研究 SCD 和/或为医院系统内的氯胺酮管理提供指导（即， 专业包括血液学、急诊医学、麻醉学和住院医学） 评估拟议 RCT 1B 的障碍和促进因素：进行半结构化 采访 15-20 名医疗保健专业人员，以评估拟议方案的障碍和促进因素 随机对照试验。